Publications by authors named "P A Klimiuk"
Background: CT-P47 is a candidate tocilizumab biosimilar that is currently in clinical development. We assessed the usability of CT-P47 self-administration via auto-injector (AI) in patients with rheumatoid arthritis (RA).
Research Design And Methods: This was a 12-week, single-arm, open-label, multiple-dose, Phase 3 study.
Efficacy and safety of CT-P47 versus reference tocilizumab: 32-week results of a randomised, active-controlled, double-blind, phase III study in patients with rheumatoid arthritis, including 8 weeks of switching data from reference tocilizumab to CT-P47.
RMD Open
October 2024
Article Synopsis
- The study aimed to show that CT-P47 is as effective as the EU-approved tocilizumab (r-TCZ) in treating rheumatoid arthritis (RA) patients.
- Conducted as a double-blind, phase III trial, 471 patients were randomized to receive either CT-P47 or r-TCZ, with efficacy measured primarily through changes in Disease Activity Score at specified weeks.
- Results indicated that both treatments had similar efficacy, pharmacokinetics, safety, and immunogenicity profiles, confirming CT-P47's equivalence to r-TCZ even after patients switched from r-TCZ to CT-P47.
Alveolar echinococcosis caused by Echinococcus multilocularis is common parasitic disease among humans and animals in the northern hemisphere. Dogs, foxes, and other wild canids are definitive hosts, whereas small rodents play the role of intermediate hosts. In rare cases, after incidental ingestion of tapeworm eggs, dogs can become an intermediate host.
View Article and Find Full Text PDFArticle Synopsis
- A study compared the safety and effectiveness of adalimumab biosimilar CT-P17 to the reference adalimumab in patients with active rheumatoid arthritis (RA) over 52 weeks.
- Results showed that efficacy rates were similar across groups, with minimal joint damage and comparable drug levels regardless of whether participants switched to CT-P17 or remained on the reference drug.
- Both CT-P17 and the reference drug exhibited similar safety profiles, and switching between them did not significantly impact immunogenicity.
Different types of canine lymphoma respond differently to chemotherapy and have different prognoses. Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma in dogs. Topoisomerase II alpha (TOPIIα) protein has been shown to be a proliferation marker associated with prognostic significance.
View Article and Find Full Text PDF